Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MM09 Immunotherapy for Mite-Induced Asthma and Rhinitis
NCT05400811Phase 3Unknown
- Sponsor
- Inmunotek
- Start
- Dec 2022
- Primary completion
- Jul 2024
- Modality
- Split/Subunit Vaccines, Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Clustoid MM09 in allergic asthma, allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Inmunotek. Primary endpoint: Combined Symptoms and Medication Score at 12 months. Status: unknown.
02
Drugs
Clustoid MM09
03
Conditions
allergic asthmaallergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT05400811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400811.